In fact, several lncRNAs affected by cancer-relevant SNPs or amplifications and deletions, including H19, PVT1,or ANRIL have been implicated in cancer drug resistance, as extensively reviewed elsewhere (Campos-Parra et al., 2018; Liu et al., 2020; Peng et al., 2020; Yuan et al., 2020). This evidence concerns the gene CDKN2B-AS1 and cancer.